남성 불임 시장 : 치료법별, 진단별, 원인별, 정자 이상 분류별, 연령층별, 최종 사용자별 시장 예측(2026-2032년)

The Male Infertility Market is projected to grow by USD 7.41 billion at a CAGR of 6.45% by 2032.

Male Infertility Market Introduction

Male infertility is a clinically significant and increasingly visible segment of reproductive health. The World Health Organization reports that infertility affects about 17.5% of adults globally, and male factors contribute to roughly half of infertility cases when combined male-female etiologies are included. This places semen analysis, hormonal evaluation, genetic testing, microsurgery, assisted reproductive technology, and lifestyle intervention at the center of a data-driven care pathway.

Demand is being shaped by delayed parenthood, rising awareness of sperm quality decline, higher use of in vitro fertilization and intracytoplasmic sperm injection, and improved access to specialist andrology services. For healthcare providers, diagnostics developers, fertility clinics, and investors, the opportunity depends on earlier diagnosis, evidence-based treatment selection, affordability, and patient-centered care that reduces stigma around male reproductive health.

Transformative Shifts in the Male Infertility Landscape

The male infertility landscape is shifting from late-stage fertility intervention to earlier, more personalized reproductive health management. The WHO Laboratory Manual for the Examination and Processing of Human Semen, 6th edition, has reinforced standardized testing, while clinicians increasingly combine semen parameters with endocrine, genetic, imaging, and lifestyle data to better identify treatable causes such as varicocele, hypogonadism, obstruction, infection, oxidative stress, and ejaculatory dysfunction.

At the same time, consumer health engagement is rising through at-home semen testing, tele-andrology, fertility preservation, and digital education. Regulatory scrutiny is also intensifying around laboratory quality, genetic data, embryo handling, and claims made by direct-to-consumer tests. The most competitive organizations are integrating clinical accuracy, transparent pricing, counseling, and coordinated care across urology and reproductive endocrinology.

Cumulative Impact of Artificial Intelligence on Male Infertility Care

Artificial intelligence is beginning to influence male infertility care through computer-assisted semen analysis, sperm morphology assessment, sperm selection research, workflow automation, predictive analytics, and patient triage. AI can help reduce observer variability in semen assessment, improve laboratory throughput, and support decision-making when combined with validated clinical inputs such as semen concentration, motility, morphology, DNA fragmentation, hormonal profiles, age, and prior reproductive history.

The cumulative impact will depend on clinical validation, bias testing, explainability, and compliance with medical device and data protection rules. AI should not replace clinical judgment, but it can improve consistency, support personalized treatment planning, and help fertility clinics identify which patients may benefit from lifestyle modification, medical therapy, microsurgery, IUI, IVF, or ICSI.

Key Regional Insights Across Male Infertility Markets

Asia-Pacific is gaining strategic importance because China and India combine large reproductive-age populations with rising fertility service capacity, while Japan, South Korea, and Australia bring advanced clinical infrastructure and strong demand linked to delayed parenthood and low birth rates. North America remains a high-value region due to established fertility clinics, CDC ART reporting in the United States, advanced genetic testing adoption, and growing employer fertility benefits, although insurance coverage remains uneven.

Europe benefits from mature ART governance, strong specialist networks, and structured oversight from national regulators such as the UK Human Fertilisation and Embryology Authority, while EU medical device and data regulations raise the bar for diagnostics and software. Latin America, led by Brazil and Mexico, is supported by private fertility care and cross-border affordability. The Middle East shows rising demand through premium IVF centers in GCC markets, while Africa remains underserved, with access gaps, infectious disease burden, and limited specialist capacity creating unmet need for male infertility diagnosis, semen analysis, and ART access.

Key Group Insights for Male Infertility Growth

ASEAN markets are becoming more relevant as Thailand, Malaysia, Singapore, Indonesia, Vietnam, and the Philippines expand fertility services at different levels of regulation and affordability. The GCC is positioned around premium clinical infrastructure, high private healthcare expenditure, and demand for culturally sensitive fertility care. The European Union offers regulatory harmonization, strong laboratory standards, and broad research capacity, making it attractive for compliant diagnostics, AI-enabled tools, and fertility preservation services.

BRICS countries combine large patient pools, expanding healthcare investment, and local manufacturing potential, but reimbursement and regulatory consistency vary. G7 economies lead in reproductive medicine research, quality systems, genetic testing, and digital health adoption. NATO is not a fertility policy bloc, but many NATO economies have resilient medical supply chains, advanced healthcare infrastructure, and defense-adjacent innovation ecosystems that can support secure data, diagnostics, and laboratory automation for male infertility care.

Key Country Insights in Male Infertility

The United States leads in advanced fertility services, genetic testing, fertility platforms, and employer-sponsored benefits, while Canada shows steady development through provincial funding models and specialist referral networks. Mexico benefits from cross-border fertility care and cost competitiveness, and Brazil remains a major Latin American fertility hub with strong private-sector capacity. The United Kingdom is shaped by HFEA oversight, Germany by strict embryo and reproductive laws, France by evolving bioethics policy, Russia by domestic capacity and supply-chain constraints, Italy by regulated ART demand, and Spain by its role as a European fertility destination.

China is expanding reproductive healthcare in response to demographic pressures, while India's ART Regulation Act and Surrogacy Regulation Act are formalizing a large and rapidly developing sector. Japan and South Korea face some of the world's lowest fertility rates, increasing policy attention on infertility treatment. Australia combines Medicare-supported care, high clinical quality, and strong patient education, making it a benchmark for integrated male and female fertility services.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based differentiation by investing in standardized semen analysis, validated genetic and hormonal testing, and multidisciplinary care models that connect urologists, reproductive endocrinologists, embryologists, genetic counselors, and mental health professionals. Organizations should also address affordability, transparent pricing, and patient navigation because delayed diagnosis and fragmented referrals remain major barriers to treatment.

Commercial strategies should focus on clinically validated AI, laboratory quality assurance, secure data governance, and compliant marketing. Partnerships with employers, insurers, academic centers, and public health programs can broaden access. Organizations that build trust through medical evidence, culturally sensitive counseling, and measurable outcomes will be better positioned than those relying on convenience alone.

Research Methodology

This executive summary is grounded in secondary research from authoritative public health, clinical, regulatory, and scientific sources, including the World Health Organization, CDC ART reporting, national fertility regulators, peer-reviewed andrology literature, and recognized reproductive medicine guidelines. The analysis emphasizes verified epidemiological facts, regulatory patterns, technology adoption signals, and regional healthcare infrastructure rather than unsubstantiated market-size claims.

The methodology applies triangulation across clinical evidence, policy developments, reimbursement context, demographic indicators, and fertility service availability. Insights were structured to support visibility while maintaining medical accuracy, using industry-relevant keywords such as male infertility treatment, semen analysis, sperm quality, assisted reproductive technology, IVF, ICSI, fertility diagnostics, and AI in reproductive medicine.

Conclusion

Male infertility is moving from an underdiagnosed condition to a strategic priority within global reproductive healthcare. The market is supported by rising infertility awareness, standardized diagnostics, wider ART utilization, and growing acceptance of male-focused fertility evaluation. However, stigma, uneven reimbursement, and variable regulatory maturity continue to shape adoption across regions.

The next phase of progress will be defined by clinically credible innovation, not isolated technology claims. Organizations that combine validated diagnostics, AI-supported workflows, personalized treatment pathways, and accessible care models will be best placed to improve reproductive outcomes and build durable leadership in male infertility care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Male Infertility Market, by Treatment Type

• 7.1. Medications
  • 7.1.1. Hormonal Therapy
  • 7.1.2. Antibiotics
  • 7.1.3. Antioxidants & Supplements
• 7.2. Surgical Treatments
  • 7.2.1. Varicocelectomy
  • 7.2.2. Vasectomy Reversal
  • 7.2.3. Obstruction Removal
• 7.3. Assisted Reproductive Technology
  • 7.3.1. Intrauterine Insemination
  • 7.3.2. In Vitro Fertilization
  • 7.3.3. Intracytoplasmic Sperm Injection
• 7.4. Lifestyle & Behavioral Interventions

8. Male Infertility Market, by Diagnosis Type

• 8.1. Semen Analysis
• 8.2. Sperm Function Tests
• 8.3. Hormonal Evaluation
  • 8.3.1. Serum Testosterone
  • 8.3.2. Follicle-Stimulating Hormone
  • 8.3.3. Luteinizing Hormone
• 8.4. Genetic Testing
• 8.5. Testicular Biopsy

9. Male Infertility Market, by Cause Type

• 9.1. Pre-Testicular
• 9.2. Testicular
• 9.3. Post-Testicular

10. Male Infertility Market, by Sperm Defect Category

• 10.1. Oligozoospermia
• 10.2. Asthenozoospermia
• 10.3. Teratozoospermia
• 10.4. Azoospermia
  • 10.4.1. Obstructive Azoospermia
  • 10.4.2. Non-Obstructive Azoospermia
• 10.5. Combined Semen Abnormalities

11. Male Infertility Market, by Age Group

• 11.1. Less Than 30 Years
• 11.2. 30 Years To 40 Years
• 11.3. More Than 40 Years

12. Male Infertility Market, by End User

• 12.1. Fertility Clinics
• 12.2. Hospitals
• 12.3. Research & Academic Institutes
• 12.4. Diagnostic Laboratories

13. Male Infertility Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Male Infertility Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Male Infertility Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. The Cooper Companies Inc
• 17.2. Merck KGaA
• 17.3. Ferring International Center S.A.
• 17.4. Thermo Fisher Scientific Inc
• 17.5. Vitrolife AB
• 17.6. Zydus Lifesciences Limited
• 17.7. Hamilton Thorne Ltd
• 17.8. Shady Grove Fertility
• 17.9. Bayer AG
• 17.10. Sun Pharmaceutical Industries Ltd
• 17.11. Andrology Solutions Ltd
• 17.12. Cadila Pharmaceuticals Ltd
• 17.13. Cook Medical LLC
• 17.14. Fairhaven Health LLC
• 17.15. FUJIFILM Irvine Scientific Inc
• 17.16. Give Legacy, Inc
• 17.17. Halotech DNA SL
• 17.18. Intas Pharmaceuticals Ltd
• 17.19. Laboratory Corporation of America Holdings
• 17.20. Lenus Pharma GesmbH
• 17.21. Mankind Pharma Ltd
• 17.22. Maze Laboratories
• 17.23. Novartis AG
• 17.24. Orthomol pharmazeutische GmbH
• 17.25. Pfizer Inc
• 17.26. SCSA Diagnostics Inc
• 17.27. Theramex HQ UK Ltd
• 17.28. Winfertility